Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Macrogenics Inc chart...

About the Company

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!

CEO

Scott Koenig

Exchange

NASDAQ

Website

https://www.macrogenics.com/

$58M

Total Revenue

415

Employees

$989M

Market Capitalization

22.77

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MGNX News

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript

4d ago, source: InvestingChannel on MSN

March 7, 2024 MacroGenics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ...

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

11d ago, source:

Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation ...

Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ...

10d ago, source:

Shares Outstanding: As of December 31, 2023, there were 62,070,627 shares of common stock outstanding.

Analyst Expectations For Macrogenics's Future

14d ago, source:

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.0, a high ...

Maintaining Market Outperform for MacroGenics with Increased Confidence in ADC Leadership and Clinical Prospects

7d ago, source:

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on MacroGenics (MGNX – Research Report), with a price target of $22.00.

AbbVie ends stay with the ADAM family, dropping MacroGenics-partnered ADC in light of early data

10d ago, source: FierceBiotech

AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate MGC936 fell short of safety and ...

Macrogenics Inc (NASDAQ: MGNX) Rise 4.02%, Now What? Don’t Panic

12d ago, source:

MGNX’s current price about 20.46% and 52.43% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 78.42, while 7-day volatility ratio ...

Insider Sell: COO Eric Risser Sells 41,159 Shares of Macrogenics Inc (MGNX)

12d ago, source: Yahoo Finance

Eric Risser, the Chief Operating Officer of Macrogenics Inc (NASDAQ:MGNX), has sold 41,159 shares of the company on March 4, ...

AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

14d ago, source:

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Stocks Rise Before the Open as Investors Await U.S. Economic Data and Powell’s Testimony, ECB Decision in Focus

11d ago, source: Barchart on MSN

Mini futures (ESH24)are up +0.17%, and March Nasdaq 100 E-Mini futures (NQH24) are up +0.22% this morning as investors looked ahead to further testimony from Federal Reserve Chair Jerome Powell while ...

MacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

11d ago, source: Finanznachrichten

4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing ...

Stocks Climb Before the Open as Investors Await U.S. Economic Data and Powell’s Testimony, ECB Decision in Focus

11d ago, source: Barchart on MSN

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...